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ABSTRACT
Disclosed herein are polymers that can be made cationic and

used to deliver a substance into a cell. Also disclosed are

pharmaceutical compositions comprising the polymers and
methods of using the polymers.
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POLYMERS FOR DELIVERINGA
SUBSTANCE INTO A CELL
CROSS-REFERENCE TO RELATED
APPLICATIONS

0001. This application claims the benefit of priority to
U.S. Provisional Application No. 61/178,654, filed on May
15, 2009, which is incorporated by reference herein in its
entirety.
STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH ORDEVELOPMENT

0002. This invention was made with U.S. Government
support under grant no. CBET 0829128 awarded by the
National Science Foundation. The government has certain
rights in the invention.
BACKGROUND

0003 Delivery vehicles are often used to delivery a sub
stance into a cell. Viruses, for example, are effective at deliv
ering DNA into mammaliancells. However, concerns regard
ing safety, immunogenicity, repeated dosage, viral
degradation, and production scale-up have motivated the
investigation of nonviral approaches for delivering a Sub
stance into a cell. A variety of nonviral delivery vehicles have
been discovered. For the delivery of anionic substances or
Substances that can be made anionic, such as therapeutic
agents, peptides, polynucleic acids, and the like, cationic
polymers are particularly useful. For example, cationic poly
mers can deliver exogenous DNA to cells and enhance the
efficacy of virus-mediated gene transfer. A few examples of
known cationic polymers used to deliver genes into cells
include poly(L-lysine), poly(ethylene imine), chitosan,
polyamidoamine or PAMAM dendrimers and poly(vinyl pyr
rolidone).
0004. Unfortunately, most cationic polymers exhibit high
cytotoxicities. As a result, alternative delivery vehicles have
been developed that exhibit lower cytotoxities, such as poly
mers based on cyclodextrin and carbohydrate comonomers,
as well as genetically engineered protein-based polymers. To
date, however, even the alternative delivery vehicles are not
optimal and are not as effective as viral delivery vehicles in
vivo. (Glover, D. J.; Lipps, H. J.; Jans, D. A. “Towards safe,
non-viral therapeutic gene expression in humans.” Nat. Rev.
Genet. 2005, 6 (4), 299-310.)
0005 Thus, both the cytotoxicity and the low efficacy of
nonviral delivery vehicles is a significant limitation in the
development of safer alternatives to viral delivery vehicles.
Accordingly, there exists a need for improved nonviral mate
rials for delivering a substance into a cell that are both effec
tive and safe. These needs and other needs are addressed by
the present invention.
SUMMARY

0006. In accordance with the purposes of the disclosed
materials, compounds, compositions, and methods, as
embodied and broadly described herein, the disclosed subject
matter, in one aspect, relates to polymers of diglycidylethers
and amines that are useful for delivering a Substance into a
cell. In a further aspect, the disclosed subject matter relates to
pharmaceutical compositions comprising both a polymer and
a substance to be delivered into a cell. In still a further aspect,
the disclosed subject matter relates to methods for delivering

a Substance into a cell using a polymer or pharmaceutical
composition. In yet a further aspect, the disclosed subject
matter relates to methods for treating a disorder by adminis
tering to a subject a polymer and a substance to be delivered
into a cell, or by administering to a subject a pharmaceutical
composition comprising a polymer and a Substance to be
delivered into a cell.

0007 Additional advantages will be set forth in part in the
description that follows, and in part will be obvious from the
description, or can be learned by practice of the aspects
described below. It is to be understood that both the foregoing
general description and the following detailed description are
exemplary and explanatory only and are not restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS

0008. The accompanying drawings, which are incorpo
rated in and constitute a part of this specification, illustrate
several embodiments of the invention and together with the
description, serve to explain the principles of the invention.
0009 FIG. 1a is a reaction scheme employed for the gen
eration of the library of eighty cationic polymers. FIG.1b is a
list of the diglycidyl ethers used in the combinatorial matrix
of the polymer library. FIG. 1c is a list of the amines used in
the combinatorial matrix of the polymer library.
0010 FIG. 2 is a three-dimensional bar plot showing
DNA-binding activity of the diglycidyl ether based cationic
polymer library determined using the ethidium bromide dis
placement assay. The percent fluorescence decreased upon
polymer binding to calf Thymus DNA intercalated with
Ethidium Bromide was used to measure polymer efficacy.
0011 FIGS. 3a-care plots demonstrating transfection of
mammalian cells using polymer leads selected from the DNA
binding screen (Example 2). Polymer transfection efficacies
are reported as relative to that of pEI-25. Relative efficacy
data are plotted on a logarithmic scale (y-axis) and statistical
significance using p-values was determined by comparing
data for a given polymer with pBI-25. (3.a) Polymer-mediated
transfection of PC3-PSMA cells in the absence of serum

using a polymer: pGL3 plasmid ratio of 25:1 (w/w). (3b)
Transfection of PC3-PSMA cells in the absence of serum

using different polymer: plasmid ratios of the 1,4C-1.4 Bis
polymer. (3.c) Polymer-mediated transfection of PC3-PSMA
cells in the presence of 10% fetal bovine serum using a
polymer: pGL3 plasmid ratio of 25:1. (3d) Polymer-mediated
transfection of murine osteoblasts using 1,4C-1.4 Bis and
pEI-25 polymers in the presence of 10% fetal bovine serum
using a polymer pGL3 plasmid ratio of 25:1.
0012 FIG. 4 is a plot displaying the percentage of dead
PC3-PSMA cells following polymer/polyplex treatment (Ex
ample 4).
0013 FIG. 5a is a plot of polymerization kinetics of
EGDE-33' and 14C-14Bis polymer formation as reported
by the disappearance of amines as a function of time. FIG.5b
is a plot obtained from fourier transform infrared (FTIR)
spectroscopy of 14C-14 Bis at polymerization at time Oh
(monomer mixture) and 16 h following initiation of the poly
mer reaction.
DETAILED DESCRIPTION

0014. The materials, compounds, compositions, articles,
devices, and methods described herein can be understood

more readily by reference to the following detailed descrip
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tion of specific aspects of the disclosed subject matter and the
Examples included therein and to the Figures.
0015. Before the present materials, compounds, composi
tions, and methods are disclosed and described, it is to be

understood that the aspects described below are not limited to
specific synthetic methods or specific reagents, as such can,
of course, vary. It is also to be understood that the terminology
used herein is for the purpose of describing particular aspects
only and is not intended to be limiting.
0016. Also, throughout this specification, various publica
tions are referenced. The disclosures of these publications in
their entireties are hereby incorporated by reference into this
application in order to more fully describe the state of the art
to which the disclosed matter pertains. The references dis
closed are also individually and specifically incorporated by
reference herein for the material contained in them that is
discussed in the sentence in which the reference is relied
upon.

0017. In this specification, reference will be made to a
number of terms, which shall be defined to have the following
meanings:
0018. Throughout the description and claims of this speci
fication the word “comprise' and other forms of the word,
Such as "comprising” and "comprises.” means including but
not limited to, and is not intended to exclude, for example,
other additives, components, integers, or steps.
0019. As used in the description and the appended claims,
the singular forms “a,” “an and “the include plural referents
unless the context clearly dictates otherwise. Thus, for
example, reference to 'acationic polymer includes mixtures
of two or more Such cationic polymers, reference to 'a Sub

between two particular units are also disclosed. For example,
if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.

0021 References in the specification and concluding
claims to parts by weight of a particular element or compo
nent in a composition denotes the weight relationship
between the element or component and any other elements or
components in the composition or article for which a part by
weight is expressed. Thus, in a compound containing 2 parts
by weight of component X and 5 parts by weight component
Y,X and Y are presentata weight ratio of 2:5, and are present
in Such ratio regardless of whether additional components are
contained in the compound.
0022. A weight percent (wt.%) of a component, unless
specifically stated to the contrary, is based on the total weight
of the formulation or composition in which the component is
included.

0023 “Optional or “optionally’ means that the subse
quently described event or circumstance can or can not occur,
and that the description includes instances where said eventor
circumstance occurs and instances where it does not.

0024. As used herein, the term “substituted” is contem
plated to include all permissible Substituents of organic com
pounds. In a broad aspect, the permissible Substituents
include acyclic and cyclic, branched and unbranched, car
bocyclic and heterocyclic, and aromatic and nonaromatic
Substituents of organic compounds. Illustrative Substituents
include, for example, those described below. The permissible
Substituents can be one or more and the same or different for

appropriate organic compounds. For purposes of this disclo
Sure, the heteroatoms, such as nitrogen, can have hydrogen
Substituents and/or any permissible Substituents of organic
compounds described herein which satisfy the valencies of

stance' includes mixtures of two or more Such substances,

the heteroatoms. This disclosure is not intended to be limited

reference to “a composition' includes mixtures of two or
more such compositions, and the like.
0020 Ranges can be expressed hereinas from “about one
particular value, and/or to “about another particular value.
When Such a range is expressed, another aspect includes from
the one particular value and/or to the other particular value.
Similarly, when values are expressed as approximations, by

compound, e.g., a compound that does not spontaneously
undergo transformation Such as by rearrangement, cycliza

use of the antecedent “about it will be understood that the

particular value forms another aspect. It will be further under
stood that the endpoints of each of the ranges are significant
both in relation to the other endpoint, and independently of
the other endpoint. It is also understood that there are a
number of values disclosed herein, and that each value is also

herein disclosed as “about that particular value in addition to
the value itself. For example, if the value “10 is disclosed,
then “about 10' is also disclosed. It is also understood that

when a value is disclosed that “less than or equal to the value,
'greater than or equal to the value' and possible ranges
between values are also disclosed, as appropriately under
stood by the skilled artisan. For example, if the value “10 is
disclosed, then “less than or equal to 10” as well as “greater
than or equal to 10” is also disclosed. It is also understood that
throughout the application data are provided in a number of
different formats and that this data represent endpoints and
starting points and ranges for any combination of the data
points. For example, if a particular data point “10 and a
particular data point “15” are disclosed, it is understood that
greater than, greater than or equal to, less than, less than or
equal to, and equal to 10 and 15 are considered disclosed as
well as between 10 and 15. It is also understood that each unit

in any manner by the permissible Substituents of organic
compounds. Also, the terms “substitution' or “substituted
with include the implicit proviso that such substitution is in
accordance with permitted valence of the substituted atom
and the substituent, and that the substitution results in a stable

tion, elimination, etc.

(0025 “A,” and “A” are used hereinas generic symbols to

represent various specific Substituents. These symbols can be
any Substituent, not limited to those disclosed herein, and
when they are defined to be certain substituents in one
instance, they can, in another instance, be defined as some
other substituents.

0026. The term “alkyl as used herein is a branched or
unbranched saturated hydrocarbon group of 1 to 24 carbon
atoms, such as methyl, ethyl, n-propyl, isopropyl. n-butyl,
isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl.
dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, and the
like. The alkyl group can also be substituted or unsubstituted.
The alkyl group can be substituted with one or more groups
including, but not limited to, alkyl, halogenated alkyl, alkoxy,
alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxy
lic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl,
sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described
below.

0027. Throughout the specification “alkyl is generally
used to refer to both unsubstituted alkyl groups and substi
tuted alkyl groups; however, Substituted alkyl groups are also
specifically referred to herein by identifying the specific sub
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stituent(s) on the alkyl group. For example, the term "halo
genated alkyl specifically refers to an alkyl group that is
Substituted with one or more halide, e.g., fluorine, chlorine,
bromine, or iodine. The term “alkoxyalkyl specifically refers
to an alkyl group that is substituted with one or more alkoxy
groups, as described below. The term “alkylamino” specifi
cally refers to an alkyl group that is substituted with one or
more amino groups, as described below, and the like. When
“alkyl is used in one instance and a specific term Such as
“alkylalcohol is used in another, it is not meant to imply that
the term “alkyl does not also refer to specific terms such as
“alkylalcohol and the like.
0028. This practice is also used for other groups described
herein. That is, while a term such as “cycloalkyl refers to
both unsubstituted and substituted cycloalkyl moieties, the
substituted moieties can, in addition, be specifically identified
herein; for example, a particular Substituted cycloalkyl can be
referred to as, e.g., an “alkylcycloalkyl.” Similarly, a substi
tuted alkoxy can be specifically referred to as, e.g., a "halo
genated alkoxy, a particular Substituted alkenyl can be, e.g.,
an “alkenylalcohol and the like. Again, the practice of using
a general term, such as “cycloalkyl and a specific term, Such
as “alkylcycloalkyl is not meant to imply that the general
term does not also include the specific term.
0029. The term “alkoxy” as used herein is an alkyl group
bound through a single, terminal ether linkage; that is, an

“alkoxy” group can be defined as —OA' where A' is alkyl as

defined above.

0030 The term alkoxylalkyl as used herein is an alkyl
group that contains an alkoxy Substituent and can be defined

as -A'-O-A, where A' and A are alkyl groups.

0031. The term “alkenyl as used herein is a hydrocarbon
group of from 2 to 24 carbon atoms with a structural formula
containing at least one carbon-carbon double bond. Asym

metric structures such as (AA)C=C(AA) are intended to

include both the E and Z isomers. This can be presumed in
structural formulae herein wherein an asymmetric alkene is
present, or it can be explicitly indicated by the bond symbol
C=C. The alkenyl group can be substituted with one or more
groups including, but not limited to, alkyl, halogenated alkyl,
alkoxy, alkenyl, alkynyl, aryl, heteroaryl, aldehyde, amino,
carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro,
silyl, Sulfo-oxo, Sulfonyl, Sulfone, Sulfoxide, or thiol, as
described below.

0032. The term “alkynyl as used herein is a hydrocarbon
group of 2 to 24 carbon atoms with a structural formula
containing at least one carbon-carbon triple bond. The alky
nyl group can be substituted with one or more groups includ
ing, but not limited to, alkyl, halogenated alkyl, alkoxy, alk
enyl, alkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic
acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, Sulfo
oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.
0033. The term “aryl as used herein is a group that con
tains any carbon-based aromatic group including, but not
limited to, benzene, naphthalene, phenyl, biphenyl, phenoxy
benzene, and the like. The term “aryl also includes “het
eroaryl, which is defined as a group that contains an aromatic
group that has at least one heteroatom incorporated within the
ring of the aromatic group. Examples of heteroatoms include,
but are not limited to, nitrogen, oxygen, Sulfur, and phospho
rus. Likewise, the term “non-heteroaryl, which is also
included in the term “aryl. defines a group that contains an
aromatic group that does not contain a heteroatom. The aryl
group can be substituted or unsubstituted. The aryl group can

be substituted with one or more groups including, but not
limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl,
aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester,
ether, halide, hydroxy, ketone, nitro, silyl, Sulfo-oxo, Sulfo
nyl, sulfone, sulfoxide, or thiol as described herein. The term
“biaryl is a specific type of aryl group and is included in the
definition of aryl. Biaryl refers to two aryl groups that are
bound together via a fused ring structure, as in naphthalene, or
are attached via one or more carbon-carbon bonds, as in

biphenyl.
0034. The term “cycloalkyl as used herein is a non-aro
matic carbon-based ring composed of at least three carbon
atoms. Examples of cycloalkyl groups include, but are not
limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
etc. The term "heterocycloalkyl is a cycloalkyl group as
defined above where at least one of the carbon atoms of the

ring is substituted with a heteroatom such as, but not limited
to, nitrogen, oxygen, Sulfur, or phosphorus. The cycloalkyl
group and heterocycloalkyl group can be substituted or
unsubstituted. The cycloalkyl group and heterocycloalkyl
group can be substituted with one or more groups including,
but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl, het
eroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide,
hydroxy, ketone, nitro, silyl, Sulfo-oxo, Sulfonyl, Sulfone,
sulfoxide, or thiol as described herein.

0035. The term "cycloalkenyl as used herein is a non
aromatic carbon-based ring composed of at least three carbon
atoms and containing at least one double bound, i.e., C=C.
Examples of cycloalkenyl groups include, but are not limited
to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopenta
dienyl, cyclohexenyl, cyclohexadienyl, and the like. The term
"heterocycloalkenyl is a type of cycloalkenyl group as
defined above, and is included within the meaning of the term
“cycloalkenyl, where at least one of the carbon atoms of the
ring is substituted with a heteroatom such as, but not limited
to, nitrogen, oxygen, Sulfur, or phosphorus. The cycloalkenyl
group and heterocycloalkenyl group can be substituted or
unsubstituted. The cycloalkenyl group and heterocycloalk
enyl group can be substituted with one or more groups includ
ing, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, aryl,
heteroaryl, aldehyde, amino, carboxylic acid, ester, ether,
halide, hydroxy, ketone, nitro, silyl, Sulfo-oxo, Sulfonyl, Sul
fone, sulfoxide, or thiol as described herein.

0036. The term “cyclic group' is used herein to refer to
either aryl groups, non-aryl groups (i.e., cycloalkyl, hetero
cycloalkyl, cycloalkenyl, and heterocycloalkenyl groups), or
both. Cyclic groups have one or more ring systems that can be
Substituted or unsubstituted. A cyclic group can contain one
or more aryl groups, one or more non-aryl groups, or one or
more aryl groups and one or more non-aryl groups.
0037. The term “aldehyde' as used herein is represented
by the formula —C(O)H. Throughout this specification
“C(O) is a short hand notation for C=O.
0038. The terms “amine' or “amino” as used herein are

represented by the formula NAAA, where A, A, and A

can be, independently, hydrogen, an alkyl, halogenated alkyl,
alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl,
heterocycloalkyl, or heterocycloalkenyl group described
above.

0039. The term “carboxylic acid as used herein is repre
sented by the formula —C(O)OH. A “carboxylate” as used
herein is represented by the formula—C(O)O.
0040. The term “ester as used herein is represented by the

formula —OC(O)A' or C(O)OA', where A' can be an
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alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl,
cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocy
cloalkenyl group described above.
0041. The term “ether as used herein is represented by the

formula A'OA, where A' and A can be, independently, an

alkyl, halogenated alkyl, alkenyl, alkynyl, aryl, heteroaryl,
cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocy
cloalkenyl group described above.
0042. The term “ketone' as used herein is represented by

the formula A'C(O)A, where A' and A can be, indepen

dently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl,
heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl group described above.
0043. The term “halideas used herein refers to the halo
gens fluorine, chlorine, bromine, and iodine.
0044) The term “hydroxyl as used herein is represented
by the formula —OH.
0045. The term "nitro” as used herein is represented by the
formula - NO.
0046. The term “silyl as used herein is represented by the

formula—SiAAA, where A, A, and Acan be, indepen

dently, hydrogen, alkyl, halogenated alkyl, alkoxy, alkenyl,
alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocy
cloalkyl, or heterocycloalkenyl group described above.
0047. The term "sulfo-oxo' as used herein is represented

by the formulas S(O)A', S(O)A', OS(O)A", or
—OS(O).OA', where A' can be hydrogen, an alkyl, haloge
nated alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl,
cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group
described above. Throughout this specification “S(O) is a
short hand notation for S=O.

0048. The term “sulfonyl' is used herein to refer to the

Sulfo-oxo group represented by the formula —S(O).A',
where A' can be hydrogen, an alkyl, halogenated alkyl, alk

enyl, alkynyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, het
erocycloalkyl, or heterocycloalkenyl group described above.
0049. The term “sulfonylamino” or “sulfonamide' as used
herein is represented by the formula—S(O)NH-.
0050. The term “sulfone' as used herein is represented by

the formula A'S(O)2A, where A' and A can be, indepen

dently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl,
heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl group described above.
0051. The term “sulfoxide’ as used herein is represented

by the formula A'S(O)A, where A' and A can be, indepen

dently, an alkyl, halogenated alkyl, alkenyl, alkynyl, aryl,
heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or
heterocycloalkenyl group described above.
0052. The term “thiol” as used herein is represented by the
formula—SH.

0053 “R',” “R” “R” “R”,” where n is an integer, as used
listed above. For example, if R is a straight chain alkyl group,

hereincan, independently, possess one or more of the groups

one of the hydrogen atoms of the alkyl group can optionally
be substituted with a hydroxyl group, an alkoxy group, an
alkyl group, a halide, and the like. Depending upon the groups
that are selected, a first group can be incorporated within
second group or, alternatively, the first group can be pendant
(i.e., attached) to the second group. For example, with the
phrase “an alkyl group comprising an amino group, the
amino group can be incorporated within the backbone of the
alkyl group. Alternatively, the amino group can be attached to
the backbone of the alkyl group. The nature of the group(s)

that is (are) selected will determine if the first group is embed
ded or attached to the second group.
0054 The terms “nucleic acid.” “polynucleic acid, and
"polynucleotide, as used herein, refer to a polymer compris
ing at least two residues of a nucleotide, which can include
any N-glycoside or C-glycoside of a purine or pyrimidine
base or of a modified purine or pyrimidine base, which
includes those bases that do not occur naturally. Specific
examples of Such polymers include without limitation any
form of ribonucleic acid (RNA), deoxyribonucleic acid
(DNA), genomic DNA, messenger RNA (mRNA), comple
mentary DNA (cDNA), antisense RNA (aRNA), a synthetic
nucleic acid polymer, or a mixture thereof, among others.
0055. Unless stated to the contrary, a formula with chemi
cal bonds shown only as solid lines and not as wedges or
dashed lines contemplates each possible isomer, e.g., each
enantiomer and diastereomer, and a mixture of isomers, such
as a racemic or scalemic mixture.

0056 Certain materials, compounds, compositions, and
components disclosed herein can be obtained commercially
or readily synthesized using techniques generally known to
those of skill in the art. For example, the starting materials and
reagents used in preparing the disclosed compounds and
compositions are either available from commercial Suppliers
such as Aldrich Chemical Co., (Milwaukee, Wis.). Acros
Organics (Morris Plains, N.J.), Fisher Scientific (Pittsburgh,
Pa.), or Sigma (St. Louis, Mo.) or are prepared by methods
known to those skilled in the art following procedures set
forth in references such as Fieser and Fieser’s Reagents for
Organic Synthesis, Volumes 1-17 (John Wiley and Sons,
1991); Rodd's Chemistry of Carbon Compounds, Volumes
1-5 and Supplementals (Elsevier Science Publishers, 1989);
Organic Reactions, Volumes 1-40 (John Wiley and Sons,
1991); March's Advanced Organic Chemistry, (John Wiley
and Sons, 4th Edition); and Larock's Comprehensive Organic
Transformations (VCH Publishers Inc., 1989).
0057 Reference will now be made in detail to specific
aspects of the disclosed materials, compounds, compositions,
articles, and methods, examples of which are illustrated in the
accompanying Examples and Figures.
0.058 As briefly discussed above, the disclosed subject
matter, in one aspect, relates to polymers that are useful for
delivering a Substance into a cell. The disclosed polymers are
both effective at delivering substances into a cell and safe
(i.e., not undesirably cytotoxic).
0059 Polymers
0060 Generally, the disclosed polymers are polymers of
diepoxide and an amine. Such as a diamine. The polymers are
generally branched at one or more points on the polymer
backbone. The amines of the polymers allow the polymers to
be made cationic by Subjecting the polymers to acid. Thus, by
reference to “polymers' herein, the cationic forms are also
contemplated. The cationic forms of the polymers can then
bind to a variety of substances that can be delivered into a cell.
0061. With reference to FIG. 1a, in one aspect, the poly
mers disclosed hereinare polymers of amines and diepoxides,
wherein the amine is represented by the formula:

NRI
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and wherein the diepoxide is represented by a formula:

v-y
wherein R' and R is independently optionally substituted

alkyl, optionally substituted cycloalkyl, optionally Substi
tuted heteroalkyl, optionally substituted heterocycloalkyl,
optionally substituted aryl, optionally substituted heteroaryl,
or a combination thereof.

0062. In specific aspects, R' is optionally substituted alkyl
amines, showing suitable variations in R', are shown in FIG.
1c. In other specific aspects, R is optionally substituted alkyl,

or heteroalkyl. Such as aminoalkyl. Specific examples of
optionally Substituted heteroalkyl. Such as ethylene glycolor
polyethylene glycol, optionally Substituted cycloalkyl, or
optionally substituted heterocycloalkyl. Specific examples of

epoxides, showing suitable variations in R, are shown in
FIG 1b.

0063. The polymers are prepared from monomers having
two or more reactive functionalities, namely epoxides and
amines, and thus ultimately have a variety of structures that
are generally branched, have one or more amines, including
secondary and tertiary amines in the polymer backbone and
primary amines as end groups, one or more secondary alco
hols (from the ring-opening of the epoxide), and/or one or
more epoxides as endgroups.
0064. With reference to FIG. 1a, the polymers are pre
pared by reacting the amine with the diepoxide, which
induces a polymerization sequence, Such as the exemplary
sequence shown in FIG. 1a, wherein either an amine end
group in a growing chain reacts with another monomeric
diglycidyl either, or a monomeric amine reacts with a glycidyl
ether endgroup, or both. The ratio of amines, glycidyl ethers,
and alcohols in the backbone can be modulated by the sto
ichiometric ratio of the monomers. The molecular weight and
structure of the polymer can be likewise modulated by not
only the monomer ratio but also by polymerization condi
tions, such as temperature or duration.
0065. In practice, the polymers can be made by reacting
the monomers in solution or neat. When it is desired to form

cationic polymers from the polymers, acid can be added to the
polymers to protonate one or more amines of the polymer. If
the polymer is in Solution, only a slight pH modification is
needed. Lowering the pH to about 7.4, for example, from a
more basic starting point, using acid will Suffice to protonate
a sufficient number of amines.

0066. With reference to FIG. 1b and FIG. 1c, specific
examples of the disclosed polymers include polymers pro
duced from any combination of monomers 1 through 8 and
monomers A-J, including copolymers 1 (i) A, 1 (i) B. 1 (i) C.
1(i) D, 1 (i) E, 1 (i) F, 1(i) G, 1(i) H, 1 (i) I, 1 (i) J: 1 (ii) A, 1(ii)
B, 1(ii) C, 1(ii) D, 1(ii) E, 1 (ii) F, 1(ii) G, 1(ii) H, 1(ii) I, 1(ii)
J; 2A, 2B, 2C, 2D, 2E, 2F, 2G, 2H, 2I, 2J: 3A, 3B, 3C, 3D, 3E,

3F, 3G, 3H, 3I, 3J; 4(i)A, 4(i)B, 4(i)C, 4(i)D, 4(i)E, 4(i)F,
4.(i)G, 4(i)H, 4(i)I, 4(i)J; 4(ii)A, 4(ii)B, 4(ii)C, 4(ii)D, 4(ii)E,
4(ii)F, 4(ii)G, 4(ii)H, 4(ii)I, 4(ii).J; 5A, 5B, 5C, 5D, 5E, 5F
5G, 5H,5I,5J; 6A, 6B, 6C, 6D, 6E, 6F, 6G, 6H, 6I, 6J; 7A,7B,
7C, 7D, 7E, 7F, 7G, 7H, 7I, 7J; 8A, 8B, 8C, 8D, 8E, 8F, 8G,

8H, 8I, 8J, and combinations thereof. In a specific aspect, the
polymer is poly(ethyleneglycol diglycidyl ether)-co-(3,3'-di
amino-N-methyl dipropylamine) or poly(1,4-cyclohex
anedimethanol diglycidyl ether)-co-1,4-bis(3-aminopropyl)

piperazine. In one aspect, the polymer is not 1 (i) A, 1 (i) B,
1(i) C, 1 (i) D, 1 (i) E, 1 (i) F. 1 (i) G, 1 (i) H, 1 (i) I, 1 (i) J. In
another aspect, the polymer is not 4(i)A, 4(i)B, 4(1)C, 4(1)D.
4.(i)E, 4(i)F, 4(i)G, 4(i)H, 4(i)I, 4(1).J.
0067. The disclosed polymers can have a number average
molecular weight (Mn) of from about 1 to about 20 kDa,
including for example, 1, 2, 3, 4, 10, 15, or 18. The disclosed
polymers can have a weight average molecular weight (Mw)
of from about 10 to about 50 kDa, including for example, 15,
20, 23, 26, 30, 35, 40, or 45. The polydispersity (Mw/Mn) of
the disclosed polymers can be from about 2 to about 7, includ
ing for example, about 3, 4 or 6.
0068. The polymers can be tested to evaluate their useful
ness as delivery agents for Substances to be delivered into a
cell using screening techniques known in the art. For
example, to evaluate the usefulness of the polymers in deliv
ering an anionic polynucleic acid. Such as DNA, into a cell,
DNA-binding efficacies of the polymers can be determined
using the ethidium bromide displacement assay, discussed
below. In vitro and/or in vivo evalutation of the polymers can
be likewise evaluated by any method known in the art.
0069 Contemplated uses of the polymers include deliver
ing a variety of Substances into a cell. As noted above, the
disclosed polymers and their cationic forms can form an
association with a substance that has an affinity therefore, and
as Such can function as a delivery vehicle for delivering the
Substance into a cell. A variety of drugs, bioactive agents,
biomolecules, such as peptides, proteins, nucleic acids, poly
nucleic acids, polynucleotides, among others, which associ
ate or can be caused to associate with a disclosed cationic

polymer, can be delivered into a cell. Peptides and proteins
include any polymer of at least two residues of a natural or
non-natural amino acid.

0070. In one aspect, the disclosed polymers can be used in
transfection procedures. Accordingly, the disclosed polymers
can be used to facilitate the intercellular delivery of DNA or
RNA sequences, for example, sequences coding for therapeu
tically active polypeptides. The disclosed polymers can also
be used to deliver a primer, promoter, TAG, or siRNA to a cell.
Likewise, disclosed polymers can be similarly used for the
delivery of an expressed gene product, such as the polypep
tide or protein itself. Thus, polymer-mediated delivery of
DNA and RNA polynucleotides or proteins can provide
therapy for genetic diseases by interfering with known
sequences or cellular activities, or by Supplying deficient or
absent gene products to treat any genetic disease in which the
defective gene or its product has been identified. The poly
mer-mediated intracellular delivery described above can also
provide immunizing polypeptides to the cell, for example, by
delivering a polynucleotide coding for the immunogen, or by
delivering the immunogen itself.
0071. Other therapeutically important nucleic acids suit
able for polymer-mediated delivery are negatively charged
oligonucleotides including antisense polynucleotide
sequences, useful in eliminating or reducing the production of
a gene product, as described by Tso, P. et al. Annals New York
Acad. Sci.570:220-241 (1987). Also disclosed is the delivery,
by means of the polymer, of ribozymes, or catalytic RNA
species, for example, the “hairpin' type as described by
Hampel et al. Nucleic Acids Research 18(2):299-304 (1990);
or the “Hammerhead' type described by Cech. T. and Bass, B.
Annual Rev. Biochem. 55:599-629 (1986). These antisense
nucleic acids or ribozymes can be expressed (replicated) in
the transfected cells. The DNA sequences delivered can be
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those sequences that do not integrate into the genome of the
host cell or those that do integrate into the genome of the host.
These can be non-replicating DNA sequences, or specific
replicating sequences genetically engineered to lack the
genome-integration ability.
0072. When the nucleic acid to be delivered is mRNA, it
can be readily prepared from the corresponding DNA in vitro.
For example, conventional techniques utilize phage RNA
polymerases SP6, T3, or T7 to prepare mRNA from DNA
templates in the presence of the individual ribonucleoside
triphosphates. An appropriate phage promoter, such as T7
origin of replication site is placed in the template DNA imme
diately upstream of the gene to be transcribed. Systems uti
lizing T7 in this manner are well known, and are described in
the literature, e.g., in Current Protocols in Molecular Biology,
S3.8 (vol. 1, 1988).
0073. In addition, disclosed herein is the delivery of
mRNA that is chemically blocked at the 5' and/or 3' end to
prevent access by RNase (this enzyme is an exonuclease and
therefore does not cleave RNA in the middle of the chain).
Such chemical blockage can Substantially lengthen the half
life of the RNA in vivo. By adding a group with sufficient bulk
to the RNA, access to the chemically modified RNA by
RNASE can be prevented.
0074. Other therapeutic uses of the polymers include the
delivery of nucleoside or nucleotide analogues having an
antiviral effect, such as dideoxynucleotides, didehydronucle
otides, nucleoside or nucleotide analogues having halo-Sub
stituted purine or pyrimidine rings such as 5-trifluoromethyl
2-deoxyuridine or 5-flurouracil; nucleoside or nucleotide
analogues having halo- and azido-substituted ribose moi
eties, such as 3’-azido-3'deoxythymidine (AZT), nucleoside
analogues having carbon Substituted for oxygen in the ribose
moiety (carbocyclic nucleosides), or nucleotide analogues
having an acyclic pentose such as acyclovir or gancyclovir
(DHPG). The antiviral potency of these analogues is found to
be increased when they are presented to the cells as phospho
lipid derivatives. Effective antiviral lipid derivatives of
nucleoside analogues comprise phosphatidyl 2',3'-dideoxy
nucleosides, 2',3'-didehydronucleosides, 3-azido-2-deoxy
nucleosides, 3-fluorodeosynucleosides and 3'-fluo
rodideoxynucleosides,
9-3-D-arabinofuranosyladenine
(araA), 1-B-D-arabinofuranosylcytidine (araC), nucleosides
Such as acyclovir and gancyclovir having an acyclic ribose
group, or the same nucleoside analogues as diphosphate dig
lyceride derivatives.
0075 Among other therapeutically important agents that
can be delivered are peptides comprising physiologic species
Such as interleukin-2, tumor necrosis factor, tissue plasmino
gen activator, factor VIII, erythropoietin, growth factors such
as epidermal growth factor, growth hormone releasing factor,
neural growth factor, and hormones such as tissue insulin,
calcitonin, and human growth hormone as well as toxic pep
tides such as ricin, diphtheria toxin, or cobra Venom factor,
capable of eliminating diseased or malignant cells.
0076 Use of the disclosed polymers is also contemplated
for the intra-cellular delivery of various other agents accord
ing to methods known to those skilled in the art, for example
as described in Duzgunes, N., Subcellular Biochemistry
11:195-286 (1985). Materials to be delivered can be proteins
or polypeptides, as discussed above, or other negatively
charged molecules, monoclonal antibodies, RNA-stabilizing
factors and other transcription and translation regulating fac
tors, antisense oligonucleotides, ribozymes, and any mol

ecule possessing intracellular activity that can also associate
with or becaused to associate with a disclosed cationic poly
mer. Polymer-mediated delivery further protects the
described agents from non-productive sequestration by Sub
stances of the extracellular environment.

(0077. The delivery procedures described herein can be
carried out in vitro, in Vivo, or ex vivo. Thus, a polymer and a
substance to be delivered into a cell can be administered

directly into a subject, as will be discussed below. Alterna
tively, a cell can be treated with a polymer and a Substance to
be delivered into the cell, followed by introducing the treated
cell into a subject to thereby treat a disorder. In another
alternative, a cell of a living organism can be removed from
the organism, treated with a polymer and a Substance to be
delivered into the cell, followed by reintroduction of the
treated cell into the organism to thereby treat a disorder.
0078. In one aspect, the polymer and/or the substance to be
delivered into the cell can be present in a pharmaceutical
composition. Local or systemic delivery of the Substance can
be achieved by administration comprising application or
insertion of the pharmaceutical composition into body cavi
ties, inhalation or insufflation of an aerosol, or by parenteral
introduction, comprising intramuscular, intravenous, intrad
ermal, peritoneal, Subcutaneous and topical administration.
The nucleic acids, for example, can be delivered to the inter
Stitial space of tissues of the animal body, including those of
muscle, skin, brain, lung, liver, spleen, bone marrow, thymus,
heart, lymph, blood, bone, cartilage, pancreas, kidney, gall
bladder, stomach, intestine, testis, ovary, uterus, rectum, ner
Vous system, eye, gland, and connective tissue. Interstitial
space of the tissues comprises the intercellular, fluid, muco
polysaccharide matrix among the reticular fibers of organ
tissues, elastic fibers in the walls of vessels or chambers,

collagen fibers of fibrous tissues, or that same matrix within
connective tissue ensheathing muscle cells or in the lacunae
of bone. It is similarly the space occupied by the plasma of the
circulation and the lymph fluid of the lymphatic channels.
The effect of the polymers in these pharmaceutical composi
tions is to enhance the potency and efficiency of the therapeu
tic agent contained therein by facilitating its intracellular
delivery.
0079. In all of the nucleic acid delivery strategies dis
closed herein, an effective DNA or mRNA dosage will gen
erally be in the range of from about 0.02 ug/kg to about 100
mg/kg, usually about 0.005-5 mg/kg. However, as will be
appreciated, this dosage will vary in a manner apparent to
those of skill in the art according to, e.g., the activity of the
peptide coded for by the nucleic acid.
0080 Topical formulations are those advantageously
applied to the skin or mucosa. Target mucosa can be that of the
gastrointestinal tract, comprising the mouth, naso-pharynx
and stomach. Other target tissues can be the accessible Sur
faces and canal of the ear and the ocular tissues. Polymers
present in topical formulations can act to facilitate introduc
tion of bioactive molecules into the target tissue. Such as the
stratum corneum of the skin, by perturbing the barrier prop
erties of the protective membrane, or by introducing perturb
ing agents or penetration enhancers such as AZOneTM or by
promoting the activity of these penetration enhancers. They
can also be delivered into muscle or skin using a vaccine gun.
I0081. Other topical compositions comprising the poly
mers are preparations comprising topical antibiotics Such as
clindamycin, tobramycin, neomycin, gentamycin, tetracy
cline, erythromycin; oxidants such as benzoyl peroxide, anti
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fungal agents, such as clotrimazole, miconazole, nystatin,
lactoconzole, econazole, and tolnaftate; retinoic acid for the

treatment of herpes simplex and comprising antiviral nucleo
side analogues such as acyclovir and gancyclovir.
0082. Other formulations comprising the disclosed poly
mers are topical preparations containing an anesthetic or
cytostatic agent, immunomodulators, bioactive peptides or
oligonucleotides, Sunscreens or cosmetics. Preparations for
topical use are conveniently prepared with hydrophilic and
hydrophobic bases in the form of creams, lotions, ointments
or gels; alternatively, the preparation can be in the form of a
liquid that is sprayed on the skin. The effect of the cationic
polymers is to facilitate the penetration of the active antiviral
agent through the stratum corneum of the dermis.
0083. Similar preparations for ophthalmic use are those in
which the pharmacologically effective agent is timolol.
betaxolol, levobunaloa, pilocarpine, and the antibiotics and
corticosteriods disclosed for topical applications.
0084. The composition and form of pharmaceutical prepa
rations comprising the polymers disclosed, in combination
with a drug or other therapeutic agent, can vary according to
the intended route of administration.

0085 Orally administered preparations can be in the form
of Solids, liquids, emulsions, Suspensions, or gels, or prefer
ably in dosage unit form, for example as tablets or capsules.
Tablets can be compounded in combination with other ingre
dients customarily used. Such as tale, vegetable oils, polyols,
gums, gelatin, starch, and other carriers. The cationic poly
mers can be dispersed in or combined with a suitable liquid
carrier in Solutions, Suspensions, or emulsions.
I0086 Parenteral compositions intended for injection,
either Subcutaneously, intramuscularly, or intravenously, can
be prepared as liquids or solid forms for Solution in liquid
prior to injection, or as emulsions. Such preparations are
sterile, and liquids to be injected intravenously should be
isotonic. Suitable excipients are, for example, water, dex
trose, Saline, and glycerol.
0087 Administration of pharmaceutically acceptable
salts of the substances described herein is included within the

Scope of the invention. Such salts can be prepared from phar
maceutically acceptable non-toxic bases including organic
bases and inorganic bases. Salts derived from inorganic bases
include Sodium, potassium, lithium, ammonium, calcium,
magnesium, and the like. Salts derived from pharmaceuti
cally acceptable organic non-toxic bases include salts of pri
mary, secondary, and tertiary amines, basic amino acids, and
the like. For a helpful discussion of pharmaceutical salts, see
S. M. Berge et al., Journal of Pharmaceutical Sciences 66:119 (1977) the disclosure of which is hereby incorporated by
reference.

0088 Substances for injection, a preferred route of deliv
ery, can be prepared in unit dosage form in ampules, or in
multidose containers. The substances to be delivered can be

present in Such forms as Suspensions, solutions, or emulsions
in oily or preferably aqueous vehicles. Alternatively, the salt
of the substance can be in lyophilized form for reconstitution,
at the time of delivery, with a suitable vehicle, such as sterile
pyrogen-free water. Both liquids as well as lyophilized forms
that are to be reconstituted will comprise agents, preferably
buffers, in amounts necessary to suitably adjust the pH of the
injected Solution. For any parenteral use, particularly if the
formulation is to be administered intravenously, the total
concentration of solutes should be controlled to make the

preparation isotonic, hypotonic, or weakly hypertonic. Non

ionic materials, such as Sugars, are preferred for adjusting
tonicity, and Sucrose is particularly preferred. Any of these
forms can further comprise Suitable formulatory agents. Such
as starch or Sugar, glycerol or saline. The compositions per
unit dosage, whether liquid or Solid, can contain from 0.1% to
99% of polynucleotide material.
I0089 Also disclosed are kits comprising the polymers and
the substance to be delivered into the cell. The kits can com

prise one or more packaged unit doses of a composition
comprising the polymer and the Substance to be delivered into
the cell. The units dosage ampules or multidose containers, in
which the polymer and the substance to be delivered are
packaged prior to use, can comprise an hermetically sealed
container enclosing an amount of polynucleotide or Solution
containing a Substance Suitable for a pharmaceutically effec
tive dose thereof, or multiples of an effective dose. The poly
mer and Substance can be packaged as a sterile formulation,
and the hermetically sealed container is designed to preserve
sterility of the formulation until use.
0090 The disclosed polymers can also be present in liq
uids, emulsions, or Suspensions for delivery of active thera
peutic agents in aerosol form to cavities of the body Such as
the nose, throat, or bronchial passages. The ratio of active
ingredient to the polymer and the other compounding agents
in these preparations will vary as the dosage form requires.
0091. Depending on the intended mode of administration,
the pharmaceutical compositions can be in the form of Solid,
semi-solid or liquid dosage forms. Such as, for example, tab
lets, Suppositories, pills, capsules, powders, liquids, Suspen
sions, lotions, creams, gels, or the like, preferably in unit
dosage form suitable for single administration of a precise
dosage. The compositions will include, as noted above, an
effective amount of the selected lipocomplex in combination
with a pharmaceutically acceptable carrier and, in addition,
can include other medicinal agents, pharmaceutical agents,
carriers, adjuvants, diluents, etc.
0092. For solid compositions, conventional nontoxic solid
carriers include, for example, pharmaceutical grades of man
nitol, lactose, starch, magnesium Stearate, Sodium saccharin,
talc, cellulose, glucose, Sucrose, magnesium carbonate, and
the like. Liquid pharmaceutically administrable composi
tions can, for example, be prepared by dissolving, dispersing,
etc., an active compound as described herein and optional
pharmaceutical adjuvants in an excipient, Such as, for
example, water, Saline aqueous dextrose, glycerol, ethanol,
and the like, to thereby form a solution or suspension. If
desired, the pharmaceutical composition to be administered
can also contain minor amounts of nontoxic auxiliary Sub
stances such as wetting or emulsifying agents, pH buffering
agents and the like, for example, Sodium acetate, Sorbitan
monolaurate, triethanolamine Sodium acetate, triethanola

mine oleate, etc. Actual methods of preparing such dosage
forms are known, or will be apparent, to those skilled in this
art; for example see Remington's Pharmaceutical Sciences,
referenced above.

0093 Parental administration, if used, is generally char
acterized by injection. Injectables can be prepared in conven
tional forms, either as liquid solutions or Suspensions, Solid
forms suitable for Solution or Suspension in liquid prior to
injection, or as emulsions. A more recently revised approach
for parental administration involves use of a slow release or
Sustained release system, Such that a constant level of dosage
is maintained. See, e.g., U.S. Pat. No. 3,710,795, which is
incorporated by reference herein.
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0094. When the polymers and substances to be delivered
into a cell are used in Subjects, the Subject can be a vertebrate,
Such as a mammal, a fish, a bird, a reptile, or an amphibian.
Thus, the subject of the herein disclosed methods can be a
human, non-human primate, horse, pig, rabbit, dog, sheep,
goat, cow, cat, guinea pig or rodent. The term does not denote
a particular age or sex. Thus, adult and newborn Subjects, as
well as fetuses, whether male or female, are intended to be

covered. A patient refers to a subject afflicted with a disease or
disorder. The term “patient' includes human and veterinary
Subjects.
EXAMPLES

0095. The following examples are put forth so as to pro
vide those of ordinary skill in the art with a complete disclo
Sure and description of how the compounds, compositions,
articles, devices and/or methods claimed herein are made and

evaluated, and are intended to be purely exemplary of the
invention and are not intended to limit the scope of what the
inventors regard as their invention. Efforts have been made to
ensure accuracy with respect to numbers (e.g., amounts, tem
perature, etc.), but some errors and deviations should be
accounted for. Unless indicated otherwise, parts are parts by
weight, temperature is in C. or is at ambient temperature,
and pressure is at or near atmospheric. Data are reported as
meantone standard deviation of independent replicate
experiments. Statistical significance was determined for a
given polymer using the unpaired Student's t-test.
Example 1
Synthesis of Cationic Polymers
0096 Eight diepoxides, 1,4 butanediol diglycidyl ether
(1.4 B), 1,4-cyclohexanedimethanol diglycidyl ether (14C),
4-vinylcyclohexene diepoxide (4VCD), ethyleneglycol dig
lycidyl ether (EDGE), glycerol diglycidyl ether (GDE), neo
pentylglycol diglycidyl ether (NPDGE), poly(ethylenegly
col) diglycidyl ether (PEGDE), and poly(propyleneglycol)
diglycidyl ether (PPGDE) were purchased from Sigma-Ald
rich and were used without any further purification. Ten
amines, 1-(2-aminoethyl)piperidine, 1,4-bis(3-aminopropyl)
piperazine, (1.4 Bis), 3,3'-diamino-N-methyl dipropylamine
(3.3"), 4,7,10-trioxa-1,13-tridecanediamine, aniline, buty
lamine, diethylenetriamine (DT), ethylenediamine (ED),
N-(2-amino ethyl)-1,3-propanediamine (N-2amino), and
pentaethylenehexamine were also purchased from Sigma
Aldrich and used as received.

0097 FIG. 1a shows the general reaction scheme
employed for the generation of the library of eighty cationic
polymers. FIG. 1b and FIG. 1c show monomers used in
developing the combinatorial matrix of the polymer library.
The eight diglycidyl ethers (2.3 mmol) were reacted with
equimolar amounts of the amines; neat as-purchased solu
tions were employed for both reactants. In the case of penta
ethylenehexamine, the low solubility of the resulting poly
mers at a 1:1 ratio of diglycidyl ether to amine necessitated
the use of a 10:1 diglycidyl ether:amine molar ratio in subse
quent experiments. The polymerization was carried out in 20
mL glass scintillation vials for 16 h. After 16 h, the resulting
polymer was diluted to a concentration of 2 mg/mL in 20 mM
Tris buffer, pH 7.4. The solution pH was adjusted to 7.4 using
30% hydrochloric acid in de-ionized (DI) water to compen
sate for the alkalinity of the polymers. Polymers that were
soluble at a concentration of 2 mg/mL at pH 7.4 were evalu
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ated for their DNA-binding efficacies. Sixteen out of the
eighty polymers synthesized were not soluble at concentra
tions of 2 mg/ml. Sixty-four soluble polymers were employed
in the primary Screening which involved an evaluation of their
respective DNA-binding efficacies using the ethidium bro
mide displacement assay.
Example 2
Screening of DNA-Binding Activity
0098. An ethidium bromide displacement assay was
employed to evaluate the DNA-binding affinity of the cat
ionic polymer library in parallel. 1.5 mL of 6 g/mL double
stranded, calf-thymus DNA was equilibrated with 15 uL of
0.5 mg/mL ethidium bromide (all solutions were prepared in
20 mM Tris buffer, pH 8.0). After equilibration, 25 L of 2
mg/mL polymer was added to the DNA-ethidium bromide
mixture and equilibrated for 20 minutes. 150 uL of the poly
mer-DNA solution was transferred into a 96-well microtiter

plate and the fluorescence (excitation at 260 nm, emission at
595 nm) was measured using a plate reader (Perkin Elmer
Lambda 6.0). The decrease in fluorescence intensity (percent
fluorescence decreased compared to control) was used to rank
DNA-binding efficacies of individual polymers. FIG.2 shows
the DNA-binding efficacy of the cationic polymer library
determined using the ethidium bromide displacement assay.
As expected, polymers based on monoamines (e.g., aniline
and butylamine) demonstrated low values of percent fluores
cent decreased (i.e., low DNA-binding efficacies) while those
derived from higher homologue polyamines, such as 1,4-Bis
(3-aminopropyl)piperazine, 3,3'-diamino-N-methyl dipropy
lamine, diethylenetriamine, and N-(2-aminoethyl)-1,3-pro
panediamine demonstrated higher efficacies. Seven
representative polymer leads, with different DNA binding
efficacies (percent fluorescence decreased values ranging
from 30% to 60%), were chosen for the transfection of PC3
PSMA cells as described below. The following references
describe the ethinium bromide displacement assay in detail:
Boger, D. L.; Fink, B. E.; Brunette, S. R.: Tse, W.C.; Hedrick,
M. P. A simple, high-resolution method for establishing DNA
binding affinity and sequence selectivity. Journal of the
American Chemical Society 2001, 123 (25), 5878-91; Geall,
A. J.; Blagbrough, I. S. Rapid and sensitive ethidium bromide
fluorescence quenching assay of polyamine conjugate-DNA
interactions for the analysis of lipoplex formation in gene
therapy. Journal of Pharmaceutical and Biomedical Analysis
2000, 22 (5),849-59; Rege, K. Hu, S.; Moore, J. A.; Dordick,
J. S.; Cramer, S. M. Chemoenzymatic synthesis and high
throughput screening of an aminoglycoside-polyamine
library: identification of high-affinity displacers and DNA
binding ligands. Journal of the American Chemical Society
2004, 126 (39), 12306-15; Rege, K.; Ladiwala, A.; Hu, S.:
Breneman, C.M.; Dordick, J.S.: Cramer, S.M. Investigation
of DNA-binding properties of an aminoglycoside-polyamine
library using quantitative structure activity relationship
(QSAR) models Journal of Chemical Information and Mod
eling 2005, 45 (6), 1854-63; each of which is incorporated
herein by this reference for teachings of the ethinium bromide
displacement assay.
Example 3
Cationic Polymer-Mediated Transfection
(0099. The pGL3 control vector (Promega Corp., Madison,
Wis., U.S.A.), which encodes for the modified firefly
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luciferase protein under the control of an SV40 promoter, was
used in transfection experiments. The PC3-PSMA human
prostate cancer cell line was provided by Dr. Michel Sadelain
of the Memorial Sloan Cancer Center, New York, N.Y., U.S.

A. The cells were cultured in a 5% CO, incubator at 37° C.
using RPMI-1640 medium containing 10% heat-inactivated
fetal bovine serum (FBS) and 1% antibiotics (10,000 units/
mL penicillin G/10,000 ug/mL streptomycin). MC3T3
murine osteoblasts were cultured in a 5% CO incubator in
Dulbecco's Modified Eagle's Medium (DMEM; BioWhit
taker(R) containing 4.5 g/L glucose and L-glutamine, Supple
mented with 10% fetal bovine serum (Invitrogen, Calif., U.S.
A.) and 1% penicillin/streptomycin (Invitrogen, Calif., U.S.
A.). PC3-PSMA and MC3T3 cells were seeded in 24-well
plates at a density of 50,000 cells/well and allowed to attach
overnight. Polymer pGL3 control plasmid at weight ratios of
25:1 (polymer concentration 10 ng/uL and 200 ng pCL3
plasmid in each well) were incubated for 30 minutes at room
temperature and the resulting polyplexes were added to cells
for 6 h either in the absence or presence of serum (10% FBS),
at the end of which, fresh serum-containing medium was
added to the cells. Following further incubation for 48 h, cells
were lysed using the Bright Glo kit (Promega) and analyzed
for luciferase protein expression (in relative luminescence
units or RLU) using a plate reader (Bio-Tek Synergy 2). The
protein content in each well was determined using the BCA
assay and the luminescence value (RLU) was normalized by
the protein content. Transfection efficacies of different poly
mers from the library were compared with the normalized
value (RLU/mg protein) obtained for pBI-25.
0100 FIG. 3a shows the transfection of PC3-PSMA cells
with the pGL3 plasmid using a set of lead polymers selected
from the DNA-binding screen. Representative polymer leads
that possessed moderate (30% fluorescence decreased) to
high (>60% fluorescence decreased) DNA binding efficacies
were employed in the transfection experiments. Calf-thymus
DNA was used only as generic double-stranded DNA in the
primary DNA binding screen for identifying lead polymers.
However, the lack of a constitutive promoter region in calf
thymus DNA implies that this DNA cannot be employed as a
reporter for transfection. Consequently, transfections were
carried out with the pGL3 control vector which codes for
luciferase protein. A polymer to plasmid ratio of 25:1 was
employed in order to evaluate the transfection efficacies of the
selected polymers. The use of nitrogen: phosphorus (N:P)
ratio is common in comparing cationic lipid and cationic
polymer meditated gene delivery. However, a w/w ratio was
used, which has been previously employed for evaluating
polymeric transfection agents.
0101. In order to evaluate polymer-mediated transfection
efficacy, luminescence (relative luminescence units or RLU)
due to the expression of the luciferase protein was normalized
to the protein content in each well, and the normalized values
were compared to those determined for pBI-25. A number of
polymers demonstrated Statistically significant higher trans
fection efficacies than pRI-25 in the absence of serum. In
particular, the 1,4C-1,4-Bispolymer, based on the monomers,
1,4-cyclohexanedimethanol diglycidyl ether (14C) and 1,4bis(3-aminopropyl)piperazine, (1.4 Bis).demonstrated
greatly (>80-fold) higher transfection efficacy than pEI-25 in
the absence of serum. Other polymers demonstrated moder
ately higher (4-8 fold) or comparable transfection efficacies
compared to that of pEI-25 in the absence of serum. For
example, Neopentylglycol diglycidyl ether-1,4-bis(3-amino

propyl)piperazine (NPGDE-14 Bis) and Ethylene glycol
diglycidyl ether-1,4-bis(3-aminopropyl)piperazine (EGDE
1.4 Bis) polymers demonstrated approximately eight-fold
higher efficacies than pEI-25. Polymers generated using 1,4bis(3-aminopropyl)piperazine (1.4 Bis) as the amine mono
mer resulted in candidates with higher gene transfection effi
cacies than pRI-25.
0102 The transfection efficacy of the 1.4 C-14Bis poly
mer was further evaluated as a function of polymer dose (i.e.
polymer:pCL3 plasmid) in the absence of serum (FIG. 3b).
While the polymer demonstrated comparable transfection
efficacies to that ofpl. I-25 at low polymer: plasmid ratios (1:1
and 5:1), transfection efficacies with higher polymer ratios
(10:1, 20:1 and 25:1) were significantly higher than those for
pEI-25. In addition to the normalized ratios presented in FIG.
3b, the actual protein expression values (i.e. RLU/mg) were
the highest observed in the experiments (not shown) when the
14C-1.4 Bis polymer was used, indicating that the polymer
resulted in greater protein expression than pEI-25 under all
conditions evaluated.

0103) A sub-set of polymers that demonstrated appre
ciable transfection efficacies in the absence of serum was

employed to transfect PC3-PSMA cells in the presence of
serum-containing media. In the presence of serum, the trans
fection efficacy dropped in all polymers evaluated. Neverthe
less, the 1.4 C-14 Bis polymer demonstrated considerably
higher efficacies (approximately 30-fold) compared to pEI
25 in the presence of serum (FIG. 3c). The transfection effi
cacies of other polymers investigated were not statistically
different compared to that of pEI-25.
0.104 Transfections were also carried out in serum-con
taining media with murine osteoblasts in order to compare the
efficacy of the 14C-1,4 Bis polymer to that of pEI-25 in cells
unrelated to human prostate cancer cells. Lower transfection
efficacies were observed in the MC3T3 murine osteoblast cell

line for both polymers (not shown) as compared to PC3
PSMA cells, reflecting the challenges of transfecting these
cells with non-viral transfection agents. However, as with the
PC3-PSMA cells, the 14 C-14 Bis polymer was more effec
tive (approximately 23-fold) than pEI-25 in transfecting these
cells (FIG.3d), indicating that the polymer might be useful in
transfecting different cell types.
Example 4
Determining Cytotoxity of Polymer and Polyplexes
0105 PC3-PSMA cells were seeded in a 24-well plate at a
density of 50,000 cells/well and incubated overnight at 37° C.
Different weight ratios of polymer-DNA polyplexes (10:1,
25:1, and 50:1 polymer: pGL3 plasmid) and different con
centrations of polymers (4-20 ng/uL) were added in the
absence of serum and the cells were incubated for 6 h to

determine polyplex- and polymer-induced cytotoxicity,
respectively. Following incubation, cells were treated with
100 uL of 4 uMethidium homodimer-1 (EthD-1: Invitrogen)
for 15 minutes and imaged immediately using Zeiss AXioOb
server D1 inverted microscope (10x/0.3 numerical aperture
(NA) objective: Carl Zeiss MicroImaging Inc., Germany).
Fluorescence using excitation at 550 run and emission at 670
nm were used for the microscopy; dead/dying cells with
compromised nuclei stained positive (red) for EthD-1.
0106 Quantitative analysis of polymer/polyplex induced
cell death was carried out as follows. The number of dead

cells in each case was counted manually for three individual
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fields of fluorescence microscopy images by means of the
Cell Counter plugin in Image.J software (Rasband, W. S.,
Image.J., U.S. National Institutes of Health, Bethesda, Md.,
USA, 1997-2005). The number of dead cells in both dead and
live controls were determined for at least two fields of view

and their average values were calculated. The number of red
fluorescent cells in the case of each polymer or the corre
sponding polyplex was determined, and the percentage of
dead cells was calculated by normalizing the number of dead
cells in the sample to number of dead cells in the dead control.
0107. With reference to FIG.4, pEI-25 was significantly
more cytotoxic when compared to the 14 C-14 Bis polymer
at concentrations of 4 ng/uL and 10 ng/LL (equivalent poly
mer: pGL3 plasmid ratios of 10:1 and 25:1). However, both
polymers demonstrated similar cytotoxicities at 20 ng/ul
(equivalent polymer: pGL3 plasmid ratios of 50:1). Interest
ingly, 1.4 C-14 Bis polymer based polyplexes (polymer:
pGL3 plasmid ratios of 10:1 and 25:1) demonstrated lower
cytotoxicities when compared to the polymer alone. In con
trast, pFI-25 based polyplexes showed comparable cytotox
icity compared to the polymer alone at all polymer pGL3
plasmid ratios investigated. The low cytotoxicities of the
14C-14 Bis polymer and its polyplex with pGL3 plasmid are
believed to be in part responsible for the higher transfection
efficacies of this polymer.
0108) Phase contrast and fluorescence microscopy images
were used to demonstrate the cytotoxicity of pl’I-25 polymer,
14C-14Bis polymer, pFI-25: pGL3 polyplex, and 14C-1,
4Bis:pGL3 polyplex toward PC3-PSMA cells in serum-free
media

Example 5
Characterization of (1,4C-14 Bis)
0109 Characterization experiments were carried out with
polymer (14C-14Bis) that demonstrated successful cellular
transfection. The polymer EGDE-3.3" was also used in some
cases in order to demonstrate the results for a different poly
mer used in transfections.

0110. The disappearance of reactive (primary and second
ary) amines with time was used to monitor the kinetics of the
diglycidyl ether-polyamine reaction (FIG.1a); the ninhydrin
assay (Friedman, M. Applications of the ninhydrin reaction
for analysis of amino acids, peptides, and proteins to agricul
tural and biomedical Sciences. Journal of Agricultural and
Food Chemistry 2004, 52 (3),385-406.60) was used to deter
mine the concentration of reactive amines at each time point.
The ninhydrin assay results in a yellow-orange color in the
case of secondary amines and a dark blue/purple color in the
case of primary amines. Approximately 2 mg of the polymers
were weighed into 1.5 mL microcentrifuge tubes (Fisher) at
different time points (0-24 h) during the polymerization reac
tion. Ninhydrin reagent (Sigma; 100 uL) and DI water (200
uL) were added to the polymers in the centrifuge tubes, fol
lowing which the tubes were placed in a boiling water bath for
10 min and cooled to room temperature (22°C.). The mixture
was diluted by adding 500 uL of 95% ethanol. The mixtures
were further diluted 10- and 100-fold using DI water in order
to obtain absorbance values within the calibration range (us
ing glycine standards) employed. Absorbance was measured
at 570 nm in triplicate for each sample using a microplate
reader (BioTek Synergy 2). The amine concentration was
monitored every 4 h, and the concentration of amines in the
reaction mixture at a given time point was normalized with
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the concentration of amines at the start of the reaction (t=0) in
order to obtain percentage amine values.
0111. The amine concentration remained largely invariant
after 12 h of reaction time as determined from the using
absorbance spectroscopy based on the formation of dark blue/
purple color following reaction with primary amines. These
results indicate that a reaction time of 16h was appropriate for
the generation of polymers that demonstrated moderate to
high DNA binding and cellular transfection efficacies. In
addition, the presence of residual primary amines (approxi
mately 30% of the initial primary amine concentration, as
reported by the dark blue color of the ninhydrin reaction),
indicated the formation of branched polymers with multiple
terminal primary amines. This was consistent with what can
be expected from the employed reaction chemistry (FIG.1a).
0112 Gel permeation chromatography was employed to
determine molecular weight values of the 14C-1,4-Bis poly
mer which were as follows: Mn) 3.9 kDa and Mw) 23.5 kDa
indicating a polydispersity (PD) of 5.96. These values indi
cated that the polymer molecular weights were comparable to
those of pl’I-25 used in the study: Mn) 10 kDa, Mw) 25 kDa,
PD) 2.5 (Sigma). Polymer molecular weight was determined
using a ViscoGEL column (MBLMW, Mixed Bed, dimen
sions: 7.8 mm x 30 cm) using 5% (v/v) acetic acid in water as
the eluent (flow rate 1 mL/min) (Joshi, A.; Saraph, A.; Poon,
V.; Mogridge, J.; Kane, R. S. Synthesis of potent inhibitors of
anthrax toxin based on poly-Lglutamic acid. Bioconjugate
Chem. 2006, 17 (5), 1265-1269.) The Mn and Mw values
were estimated as an average of two experimental runs using
a light scattering Viscotek 270 Trisec Dual Detector;
OmniSEC software, ) 670 nm.
0113 Formation of the 14C-14Bis polymer was further
verified using Fourier transform infrared (FT-IR) spectros
copy by following the appearance and disappearance of cer
tain bands as a function of reaction time. FT-IR spectra were
obtained at two different polymerization time points (t=0 and
t=16 h) in order to ascertain the formation of the polymers.
Polymer samples were loaded on a germanium attenuated
total reflectance (GATR) crystal such that they covered the
center area of the crystal. The sample chamber was equili
brated to approximately 4 mbar pressure in order to minimize
interference from atmospheric moisture and CO. The
absorption spectrum was measured between 650 and 4,000
cm-1 using a Broker IFS 66 V/S FT-IR spectrometer and the
background spectrum was subtracted from all sample spectra.

I0114. The epoxide peak ranging from 858 to 918 cm can
be seen in the monomer mixture at time t-Oh (FIG.5b) due to
stretching and contraction of C-O bonds in the epoxide
moiety. However, this peak is significantly reduced after 16 h
of reaction time, indicating a reduction in the epoxide content
upon formation of the cationic polymer (Loos, M. R.: Coelho,
L. A. F.; Pezzin, S. H.; Amico, S. C. The effect of acetone

addition on the properties of epoxy. Polimeros: Ciencia e
Tecnologia 2008, 18 (1), 76-80). Characteristic spectral
bands of primary amines were seen at 1100-1128 and 3358

3382 cm due to the presence of C N and N-H bonds,
respectively. The broadbands from 3382-3402 cm upon 16

h of reaction time can be attributed to hydroxyl (—OH)
groups generated upon reaction of the epoxy rings with pri
mary and secondary amines. Taken together, FT-IR analysis
further confirmed that the diglycidyl ether-polyamine reac
tion resulted in the formation of the 14C-14Bis polymer that
demonstrated high transfection efficacies in vitro.
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What is claimed is:

1. A composition, comprising, a polymer of a diepoxide
and an amine, wherein the diepoxide is
a. 14butanediol diglycidyl ether (14 B);
b. 1.4-cyclohexanedimethanol diglycidyl ether (14C);
c. 4-vinylcyclohexene diepoxide (4VCD);
d. ethyleneglycol diglycidyl ether (EDGE):
e.glycerol diglycidyl ether (GDE);
f. neopentylglycol diglycidyl ether (NPDGE):
g. poly(ethyleneglycol) diglycidyl ether (PEGDE); or
h. poly(propyleneglycol) diglycidyl ether (PPGDE); and
wherein the amine is

i. 1-(2-aminoethyl)piperidine;
j. 1,4-bis(3-aminopropyl)piperazine (1.4 Bis);
k. 3,3'-diamino-N-methyl dipropylamine (3.3");
1. 4,7,10-trioxa-1,13-tridecanediamine;
m. aniline;

n.butylamine;
o. diethylenetriamine (DT);
p. ethylenediamine (ED);
q. N-(2-aminoethyl)-1,3-propanediamine (N-2amino); or
r. pentaethylenehexamine.
2. The composition of claim 1, wherein the polymer has a
number average molecular weight (Mn) of from about 1 to
about 20 kDa.

3. The composition of claim 1, wherein the polymer has a
weight average molecular weight (Mw) of from about 10 to
about 50 kDa.

4. The composition of claim 1, wherein the polymer has a
polydispersity index (PDI) of from about 2 to about 7.
5. The composition of claim 1, wherein the polymer is
cationic.

6. The composition of claim 1, further comprising a Sub
stance to be delivered into a cell.

7. The composition of claim 6, wherein the substance is a
nucleic acid.

8. The composition of claim 1, wherein the polymer is
poly(ethyleneglycol diglycidyl ether)-co-(3,3'-diamino-Nmethyl dipropylamine) or poly(1,4-cyclohexanedimethanol
diglycidyl ether)-co-1,4-bis(3-aminopropyl)piperazine.
9. A pharmaceutical composition, comprising, a polymer
of a diepoxide and an amine, wherein the diepoxide is
a. 14butanediol diglycidyl ether (14 B);
b. 1.4-cyclohexanedimethanol diglycidyl ether (14C);
c. 4-vinylcyclohexene diepoxide (4VCD);
d. ethyleneglycol diglycidyl ether (EDGE):
e.glycerol diglycidyl ether (GDE);
f. neopentylglycol diglycidyl ether (NPDGE):
g. poly(ethyleneglycol) diglycidyl ether (PEGDE); or
h. poly(propyleneglycol) diglycidyl ether (PPGDE); and
wherein the amine is

i. 1-(2-aminoethyl)piperidine;
j. 1,4-bis(3-aminopropyl)piperazine (1.4 Bis);
k. 3,3'-diamino-N-methyl dipropylamine (3.3");
1. 4,7,10-trioxa-1,13-tridecanediamine;
m. aniline;

n.butylamine;

o. diethylenetriamine (DT);
p. ethylenediamine (ED);
N-(2-aminoethyl)-1,3-propanediamine (N-2amino); or
r. pentaethylenehexamine; and
and a substance to be delivered into a cell.

10. The pharmaceutical composition of claim 9, wherein
the polymer has a number average molecular weight (Mn) of
from about 1 to about 20 kDa.

11. The pharmaceutical composition of claim 9, wherein
the polymer has a weight average molecular weight (Mw) of
from about 10 to about 50 kDa.

12. The pharmaceutical composition of claim 9, wherein
the polymer has a polydispersity index (PDI) of from about 2
to about 7.

13. The pharmaceutical composition of claim 9, wherein
the polymer is cationic.
14. The pharmaceutical composition of claim 9, wherein
the Substance is a nucleic acid.

15. A method for delivering a nucleic acid into a cell,
comprising, contacting a cell withi.) a polymer of a diepoxide
and an amine; and ii.) a nucleic acid;
wherein the diepoxide is
a. 14butanediol diglycidyl ether (14 B);
b. 1.4-cyclohexanedimethanol diglycidyl ether (14C);
c. 4-vinylcyclohexene diepoxide (4VCD);
d. ethyleneglycol diglycidyl ether (EDGE):
e.glycerol diglycidyl ether (GDE);
f. neopentylglycol diglycidyl ether (NPDGE):
g. poly(ethyleneglycol) diglycidyl ether (PEGDE); or
h. poly(propyleneglycol) diglycidyl ether (PPGDE):
and
wherein the amine is

i. 1-(2-aminoethyl)piperidine;
j. 1,4-bis(3-aminopropyl)piperazine (1.4 Bis);
k. 3,3'-diamino-N-methyl dipropylamine (3.3");
1. 4,7,10-trioxa-1,13-tridecanediamine;
m. aniline;

n.butylamine;
o. diethylenetriamine (DT);
p. ethylenediamine (ED);
q. N-(2-aminoethyl)-1,3-propanediamine (N-2amino);
O

r. pentaethylenehexamine.
16. The method of claim 15, wherein the polymer has a
weight average molecular weight (Mw) of from about 10 to
about 50 kDa.

17. The method of claim 15, wherein the polymer has a
polydispersity index (PDI) of from about 2 to about 7.
18. The method of claim 15, wherein the polymer is cat
ionic.

19. The method of claim 15, wherein the polymer is poly
(ethyleneglycol diglycidyl ether)-co-(3,3'-diamino-N-me
thyl dipropylamine) or poly(1,4-cyclohexanedimethanol dig
lycidyl ether)-co-1,4-bis(3-aminopropyl)piperazine.
20. The method of claim 15, wherein the polymer and the
nucleic acid together form a polyplex.
c

c

c

c
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